Ansa Biotechnologies Expands Successful Early Access Program for Complex DNA Synthesis
Reliable enzymatic synthesis service overcomes limitations associated with legacy technologies, allowing scientists to significantly increase the design space that... Read more.
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
SAN DIEGO–(BUSINESS WIRE)–Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver... Read more.
Westaim Announces Sale of Skyward Specialty Shares Under Secondary Offering
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO... Read more.
Block, Inc. Announces $1.5 Billion Offering of Senior Notes
DISTRIBUTED-WORK-MODEL/OAKLAND, Calif.–(BUSINESS WIRE)–Block, Inc. (“Block”) (NYSE: SQ) today announced its intention to offer, subject to market... Read more.
POTTERY BARN LAUNCHES NEW COASTAL LOOKBOOK FOR SUMMER
New Lookbook Showcases Curated Collection of Exclusive Products Designed for Effortless Summer Living Year Round SAN FRANCISCO–(BUSINESS WIRE)–Pottery... Read more.
Pressed Juicery Selects NCR Voyix Solutions to Squeeze Greater Value Out of its Technology
ATLANTA–(BUSINESS WIRE)–$VYX #JuicyCollaboration–Pressed Juicery, a pioneer in cold-pressed juices and wellness offerings, is proud to announce... Read more.
Genesis Energy, L.P. Announces Public Offering of Senior Notes
HOUSTON–(BUSINESS WIRE)–Genesis Energy, L.P. (NYSE: GEL) today announced the commencement, subject to market and other conditions, of a registered, underwritten... Read more.
Genesis Energy, L.P. Announces Public Offering of Senior Notes
HOUSTON–(BUSINESS WIRE)–Genesis Energy, L.P. (NYSE: GEL) today announced the commencement, subject to market and other conditions, of a registered, underwritten... Read more.
Tokens.com to Release its Financial Results for Q2-2024 on May 9, 2024
TORONTO–(BUSINESS WIRE)–Tokens.com Corp. (“Tokens.com” or the “Company”) (TSX-V: COIN) (Frankfurt Stock Exchange: 76M) (OTCQB US: SMURF), a technology... Read more.
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
– Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory and $180 million in sales milestones... Read more.